New England Journal of Medicine (NEJM) , found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a 27 percent reduction in risk of disease progression or death compared with the current standard of care of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) therapy.
↧